Literature DB >> 26794023

Intrinsic thermodynamics of inhibitor binding to human carbonic anhydrase IX.

Vaida Linkuvienė1, Jurgita Matulienė1, Vaida Juozapaitienė1, Vilma Michailovienė1, Jelena Jachno1, Daumantas Matulis2.   

Abstract

BACKGROUND: Human carbonic anhydrase 9th isoform (CA IX) is an important marker of numerous cancers and is increasingly interesting as a potential anticancer drug target. Various synthetic aromatic sulfonamide-bearing compounds are being designed as potent inhibitors of CA IX. However, sulfonamide compound binding to CA IX is linked to several reactions, the deprotonation of the sulfonamide amino group and the protonation of the CA active site Zn(II)-bound hydroxide. These linked reactions significantly affect the affinities and other thermodynamic parameters such as enthalpies and entropies of binding.
METHODS: The observed and intrinsic affinities of compound binding to CA IX were determined by the fluorescent thermal shift assay. The enthalpies and entropies of binding were determined by the isothermal titration calorimetry.
RESULTS: The pKa of CA IX was determined to be 6.8 and the enthalpy of CA IX-Zn(II)-bound hydroxide protonation was -24 kJ/mol. These values enabled the analysis of intrinsic thermodynamics of a library of compounds binding to CA IX. The most strongly binding compounds exhibited the intrinsic affinity of 0.01 nM and the observed affinity of 2 nM.
CONCLUSIONS: The intrinsic thermodynamic parameters of compound binding to CA IX helped to draw the compound structure to thermodynamics relationship. GENERAL SIGNIFICANCE: It is important to distinguish the intrinsic from observed parameters of any disease target protein interaction with its inhibitors as drug candidates when drawing detailed compound structure to thermodynamics correlations.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Benzenesulfonamide inhibitors; Carbonic anhydrase; Drug design; Fluorescent thermal shift assay; Intrinsic thermodynamics of protein-ligand binding; Isothermal titration calorimetry

Mesh:

Substances:

Year:  2016        PMID: 26794023     DOI: 10.1016/j.bbagen.2016.01.007

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

1.  Intrinsic thermodynamics of high affinity inhibitor binding to recombinant human carbonic anhydrase IV.

Authors:  Aurelija Mickevičiūtė; David D Timm; Marius Gedgaudas; Vaida Linkuvienė; Zhiwei Chen; Abdul Waheed; Vilma Michailovienė; Asta Zubrienė; Alexey Smirnov; Edita Čapkauskaitė; Lina Baranauskienė; Jelena Jachno; Jurgita Revuckienė; Elena Manakova; Saulius Gražulis; Jurgita Matulienė; Enrico Di Cera; William S Sly; Daumantas Matulis
Journal:  Eur Biophys J       Date:  2017-10-03       Impact factor: 1.733

2.  An update on anticancer drug development and delivery targeting carbonic anhydrase IX.

Authors:  Justina Kazokaitė; Ashok Aspatwar; Seppo Parkkila; Daumantas Matulis
Journal:  PeerJ       Date:  2017-11-23       Impact factor: 2.984

Review 3.  Biophysical, Biochemical, and Cell Based Approaches Used to Decipher the Role of Carbonic Anhydrases in Cancer and to Evaluate the Potency of Targeted Inhibitors.

Authors:  Mam Y Mboge; Anusha Kota; Robert McKenna; Susan C Frost
Journal:  Int J Med Chem       Date:  2018-07-16

4.  New Monoclonal Antibodies for a Selective Detection of Membrane-Associated and Soluble Forms of Carbonic Anhydrase IX in Human Cell Lines and Biological Samples.

Authors:  Dovile Stravinskiene; Aiste Imbrasaite; Vilma Petrikaite; Daumantas Matulis; Jurgita Matuliene; Aurelija Zvirbliene
Journal:  Biomolecules       Date:  2019-07-25

5.  Switching the Inhibitor-Enzyme Recognition Profile via Chimeric Carbonic Anhydrase XII.

Authors:  Joana Smirnovienė; Alexey Smirnov; Audrius Zakšauskas; Asta Zubrienė; Vytautas Petrauskas; Aurelija Mickevičiūtė; Vilma Michailovienė; Edita Čapkauskaitė; Elena Manakova; Saulius Gražulis; Lina Baranauskienė; Wen-Yih Chen; John E Ladbury; Daumantas Matulis
Journal:  ChemistryOpen       Date:  2021-05       Impact factor: 2.630

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.